A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases
Clinical trial NCT04643847 · UNKNOWN
Trial details
- NCT number
- NCT04643847
- Sponsor
- First People's Hospital of Hangzhou
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-30
- Primary completion
- 2022-11-30
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.